Gator:It is odd that MAKO just hasn't made much splash in academics. One would think from the company's perspective, they would be incentivized to practically give them away to academic sites if not for any other reason that to train a huge next gen population of orthopedics doctors. I don't buy the pragmatist TALC argument for academics adoption.......these doctors live in a malpractice mitigated world, seek any publications and fame they can get.......makes no sense they would deliberately avoid a new paradigm in joint surgery.I would suspect MAKO's cost to build a robot at around $500,000 so pick 20 academic sites and donate them for total cost of $10 million......what the heck.But I would point out that contrary to what many here have suggested, there are reams of various quality studies on DaVinci.......can toggle through a few here:http://link.springer.com/search/page/1?facet-journal-id=1170...Despite this being a Journal of Robotic surgery......no real mention of MAKO in the reams of studies.I have suspected all along that the lack of sufficient studies for MAKO was reflective of their strategic misstep to concentrate entirely on unicompartment disease which practically every orthopedics doctor seems skeptical of regardless. The population is also too few to build a center of excellence concept.Now with their seminal strategic shift to total hips, total knees and uni/bicmpartments........we should see a huge shift in interest. I was able to speak with a surgeon who does MAKO last year and one can see the need to expand indications......if MaKO has any chance of success or survival.It has been a while since I looked at their cash burn rates but they don't seem that close to cash positive.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Ma